Trump adds pressure on new stadium deal for NFL Commanders
Trump said he wants to see the team restore the old nickname and called upon Major League Baseball's Cleveland Guardians to revert to their old nickname of Indians in weekend social media posts.
"I may put a restriction on them that if they don't change the name back to the original 'Washington Redskins,' and get rid of the ridiculous moniker, 'Washington Commanders,' I won't make a deal for them to build a Stadium in Washington," Trump posted.
Washington's City Council is studying plans before voting on final approval for a deal struck by the club and Mayor Muriel Bowser to build a new 65,000-seat domed venue on the site of RFK Stadium, the club's former home before it moved to the Maryland suburbs.
Asked Monday about Trump's threat, Bowser said a name change by the club would not alter her support of the deal. Instead, she ripped the council for delays on approving the stadium deal that would rely on about $1.1 billion in taxpayer funds.
"What I'm concerned about is we haven't done our part and so we need to complete our part so that the team can get to work so that local businesses can get hired so that we can start earning the tax revenue that will come when we deliver the Commanders' stadium," Bowser said.
Phil Mendelson, chair of the DC Council, said in a statement that Trump's threat would not push the council's timeline for considering all aspects of the deal, including at a hearing next week.
"I am focused on getting the best deal for District taxpayers and getting the deal across the finish line," he said. "I have heard from no -- zero -- District residents complaining about the name change or saying this is an issue in connection with the stadium."
The RFK Stadium site for the proposed new stadium is on federal land but US lawmakers gave control of the site to the city last year.
Trump, who said the team would be more valuable by reverting to its prior nickname, could impact the deal through US federal committees that approve DC construction projects.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
2 hours ago
- Euronews
EU-US trade deal leaves future of pharma tariffs uncertain
The current status of tariffs on pharmaceuticals between the EU and the US remains uncertain, despite the announcement on Sunday of a new transatlantic trade agreement. The situation is particularly sensitive given the mutual dependency in the sector: the US imports large volumes of critical pharmaceuticals from the EU, while EU-based pharmaceutical companies—especially in Ireland and Denmark—rely heavily on access to the American market. Although the new trade agreement will officially enter into force on 1 August, pharmaceuticals will not be subject to a 15% tariff which will be slapped on most goods imported from the European Union to the United States. This does not mean that there won't be tariffs at all on pharmaceuticals, as the US is still conducting an investigation into imported pharmaceuticals to assess whether they threaten US national security. For this reason, pharmaceuticals were technically excluded from yesterday's formal agreement, several EU sources confirm, as the US could not commit to any decision on tariff changes, which will only come after the conclusion of that process. However, if tariffs are introduced following the investigation, the EU expects the US—under President Trump—to honour the informal understanding reached during negotiations. This includes a cap of 15% on tariffs, which the EU considers "all-inclusive", meaning it should apply even to products still under investigation, such as pharmaceuticals and semiconductors. 'I believe that this commitment will be honoured and respected in this case as well,' said EU Trade Commissioner Maroš Šefčovič during a press briefing following the deal. So, what happens after 1 August? In the short term, nothing will change. Despite earlier reports suggesting the US would impose a 15% tariff on pharmaceuticals too in line with most EU goods, that is not expected to happen immediately. 'There will be no tariffs on pharmaceuticals this Friday,' clarified a senior EU official who participated in the negotiations with President Trump in Scotland. Most pharmaceutical products traded between the EU and the US currently benefit from a 0% tariff rate under the Most-Favoured Nation (MFN) framework. This is consistent with prior US-EU trade arrangements and World Trade Organization (WTO) commitments. As a result, EU pharmaceutical exports have faced no tariff barriers when entering the US market—a condition that remained unchanged even after Trump's so-called "Liberation Day", when he announced imposing blanket tariffs on goods. Uncertain outcome of the US investigation But tariffs on pharmaceuticals are expected to come at one point. The key uncertainty revolves around the ongoing Section 232 investigation being conducted by the Trump administration. This probe, authorised under the Trade Expansion Act of 1962, is intended to assess whether imports of pharmaceuticals (and other products as well such as semiconductors) threaten US national security. The investigation's conclusions could lead to unilateral actions by the US, including higher tariffs or import restrictions, independent of the broader trade deal struck yesterday. '[During the talks] President Trump wanted to make clear that they still have full freedom to conclude the 232 investigations and to choose any policy measures as a result,' said another EU negotiator. While EU officials cannot predict the outcome of the US investigation, they believe it is nearing completion. 'These are two investigations—pharmaceuticals and semiconductors—that are pretty close to conclusion,' an official noted. If the US does impose tariffs following the investigation, the EU expects these to be capped at 15% for both sectors, in line with the political understanding reached during the trade talks. EU's bet on pharma tariffs The EU's strategy is clear: even though Trump could not legally commit yesterday to tariffs on pharmaceuticals while the investigation is ongoing, the EU insisted on a 15% ceiling across all sectors, with no exclusions for pharmaceuticals. A senior EU official added that this understanding is backed by a broader political commitment, including planned investments by pharmaceutical companies in the US and pressure from the industry on both sides of the Atlantic to collaborate more closely. 'There is a clear understanding that investments, supply chain integration, and joint R&D efforts should all fall under the special 15% regime,' the official explained. Still, the EU acknowledges that this is not yet a legally binding commitment. 'Is this a legal commitment? No, not at this stage. That would have to come through an executive order once the US concludes its investigation,' the source continued. For now, both pharmaceutical and semiconductor products remain at zero-duty 0rates. No changes will occur on 1 August, but that could change once the US finalises its Section 232 investigation.
Euronews
2 hours ago
- Euronews
Oil prices rise on EU-US trade deal and Trump comments on Ukraine
Oil prices rose on Monday afternoon in Europe after US President Donald Trump said he would reduce the deadline for Russian President Vladimir Putin to reach a peace deal with Ukraine. WTI was up around 2.2% at $66.50 a barrel, while Brent crude oil was up around 2% at $69.80, as of 15.00 CEST. Trump issued the 50-day timeline to Putin in July, claiming that he would hit Russia with a 100% tariff if Moscow didn't end the war in Ukraine. 'I'm disappointed in President Putin, very disappointed in him. So we're going to have to look and I'm going to reduce that 50 days that I gave him to a lesser number,' Trump told reporters in Scotland on Monday. 'I think I already know the answer, what's going to happen,' Trump said. The president was preparing to meet UK Prime Minister Keir Starmer. Oil prices had risen earlier in the day on Monday as investors reacted to news of a EU-US trade deal, announced on Sunday. Among other provisions, the EU agreed to buy $750 billion of US energy products, including oil, LNG, and nuclear energy over three years. The deal means that the EU will face a 15% tariff on most of its goods when Trump's tariff deadline ends on 1 August, rather than a threatened 30% rate. European stock markets also jumped during Monday morning trading on the news, before settling in the afternoon. Trump's tariff threats have previously deflated oil prices this year as investors predicted that a potential economic slowdown could affect demand for oil. Geopolitical risk, on the other hand, has stoked prices in cases where investors have expected threats to supply. US attacks on Iran's nuclear facilities, for example, prompted a spike in oil prices in June. An OPEC+ committee meeting is taking place on Monday, where participants will decide on production policy for September. Both the International Energy Agency and the US Energy Information Administration expect a strong oil surplus next year, with supply outpacing demand. After securing a deal with the EU, Washington has now set its sights on negotiations with China. US Treasury Secretary Scott Bessent and US Trade Representative Jamieson Greer are meeting with Chinese officials, including Chinese Vice Premier He Lifeng, on Monday in Stockholm. China and the US agreed to temporarily lower reciprocal tariffs during a 90-day truce period, set to expire on 12 August. There are hopes that the two nations will be able to extend the grace period, with China currently taxing US goods at 10% and the US taxing Chinese goods at 30%.
Euronews
2 hours ago
- Euronews
'Best we could get': Brussels defends EU-US deal as criticism mounts
The European Commission is scrambling to defend the trade deal struck by Ursula von der Leyen and Donald Trump amid mounting criticism over its lopsided nature, arguing the tentative compromise represents the most realistic chance to avert a havoc-wreaking tariff war between the two sides of the Atlantic. "This is clearly the best deal we could get under very difficult circumstances," Maroš Šefčovič, the European Commissioner for Trade, said at a press conference on Monday. The announced deal foresees the introduction of an across-the-board 15% tariff for EU products bound for the US market. At the same time, the majority of US products bound for the EU market will benefit from a zero or virtually zero tariff. Sensitive agricultural goods, such as beef, poultry and sugar, were excluded from the agreement. The 15% rate is lower than the 30% rate that Trump threatened to slap on the bloc in a letter sent to von der Leyen earlier this month. It is also below the 20% rate that he originally announced in April as part of his controversial "reciprocal tariffs". However, it is significantly higher than the average 4.8% rate that EU exports faced upon entering US soil before Trump's return to the White House. According to Šefčovič, who sat next to von der Leyen during Sunday's make-or-break meeting, Trump kicked off the negotiations by putting the 30% again on the table. This led to a back-and-forth between the two sides until they settled for the 15% mark, applicable as "all inclusive" to block the accumulation of additional duties. Trump's 30% tariff, Šefčovič said, would have effectively halted transatlantic trade and created an "unbearable" situation with "much worse conditions" for the talks. "It's quite obvious that the world which was there before 2 April is gone. And we simply need to adjust, we need to address the challenges which are coming from this new approach," the Commissioner said. "And I believe that the strategic cooperation with our strategic partner is a better outcome than an all-out trade war." 'Between the plague and cholera' The Commission's version of events has so far failed to quell the simmering discontent. The stark difference between the 15% rate imposed on most EU goods and the 0% rate enjoyed by most US goods has fuelled the impression of an asymmetrical arrangement that exclusively favours Trump's interests to the detriment of the bloc's. The pledges to spend $700 billion in US energy and invest $600 billion in the US economy until the remainder of Trump's second term have only deepened the impression of a win-lose deal. (The pledges are indicative, not legally binding.) Bernd Lange, a German MEP who chairs the European Parliament's trade committee and is in regular contact with Šefčovič, left no doubt as to his displeasure. "My first assessment: not satisfactory. This is a lopsided deal. Concessions have clearly been made that are difficult to accept," Lange said on social media. Kathleen Van Brempt, who serves as one of the committee's vice-chairs, was more scathing, warning the deal would make the bloc more "dependent" on American fuels and ultimately "backfire" against its stated goal of strategic autonomy. "The fundamental problem remains that Trump's tariffs are illegal and violate virtually every existing trade rule," Van Brempt wrote in a statement. "Simply accepting that European products will be subject to a 15% import tariff (...) means that we are essentially agreeing to these illegal, coercive tariffs. "Avoiding a heavier 30% tariff will undoubtedly be a relief," she added. "But this remains a choice between the plague and cholera." Decrying a "heavy price" paid, Valérie Hayer, the president of the liberal Renew Europe group, said the agreed terms would lead to a "massive imbalance" between the two sides, and Terry Reintke, co-chair of the Greens, slammed the Commission for caving into "the bullying tactics and threats of President Trump". "This is not the way to do business," Reintke said. Even von der Leyen's party, the centre-right European People's Party (EPP), was unhappy with the outcome, calling the 15% a "blatant breach of WTO principles and a serious blow to European industrial competitiveness". 'A dark day' EU leaders were noticeably lukewarm in their initial reactions, welcoming the deal as an anchor of "stability" but lamenting the continuation of the punitive duties. "This is a moment of relief but not of celebration. Tariffs will increase in several areas, and some key questions remain unresolved," said Belgian Prime Minister Bart de Wever. His Dutch counterpart, Dick Schoof, said that "no tariffs would have been better", while Ireland's Micheál Martin, whose country strongly relies on the US market, predicted trade would become "more expensive" and "more challenging". Spain's Pedro Sánchez was visibly apathetic. "In any case, I support this trade agreement, but I do so without any kind of enthusiasm," he said. In France, the prime minister described the agreement as a "dark day" of "submission". The remarks expose the feeling of despondency and frustration that has gripped the EU since the start of Trump's second term. The Republican has single-handedly bulldozed over decades of transatlantic principles to promote his "America First" agenda, breaking with the Western consensus on trade, technology, climate and defence. In his press conference, Šefčovič said geopolitics had played a role in the Commission's balancing act ahead of the face-to-face meeting in Scotland. "It's not only about the trade. It's about security. It is about Ukraine. It is about current geopolitical volatility," he said. "I believe from now on, we can go only for the better." Privately, Commission officials concede the 15% rate is "not great" and hope Washington will treat the tariff as a maximum ceiling to prevent escalation down the road. But Peter Chase, a senior fellow at the German Marshall Fund, says Brussels should do better than take things for granted, given Trump's notoriously mercurial character. "Unfortunately," Chase said, "President von der Leyen and others who believe the EU's concessions bought stability for European businesses may unfortunately find that the man who shredded US commitments under international law to create 'leverage' is very likely to rip up this agreement too."
